Anemia
Adverse Event of FG-2216 for the Treatment of Anemia
Published in Blood Weekly, May 24th, 2007
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that in the phase II clinical trial of FG-2216 (development code. Astellas code name: YM 311) for patients in pre-dialysis chronic kidney disease being conducted in the United States by FibroGen, Inc. ("FibroGen": headquarters: South San Francisco, CA; Chairman, founder and CEO: Thomas B. Neff), there was one case of death by fulminant hepatitis. FG-2216 is a compound for oral anemia treatment for which Astellas has licensed from FibroGen fro exclusive development and marketing in Japan and Europe, etc.
FibroGen has reported this case to the FDA and will be discussing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-05-24)
More Articles from Blood Weekly
- Anemia
Advances in Transplant Medicine Make First Mother’s Day a Reality for Parents of Twins - Artificial Organs
HepaLife Expands Management Team on Heels of Favorable Outcomes of First-of-Its-Kind Bioartificial Liver Device - ASPE)
State Senator Announces Formation of Patient, Physician, Industry Alliance to Solve Problems of Access to Human Plasma-Based Therapies - Clinical Trial Research
Isotechnika Selected for Oral Presentation at the American Transplant Congress - Coagulation
HemoSense and ZyCare Partner with Pima Heart to Utilize Web-Based Warfarin Patient Management System for INRatio - Coagulation
Rex Medical Announces the Successful Retrieval of the Option Vena Cava Filter up to Day 225 in an International Clinical Study - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
